Mannkind

Only the FDA could come up with clinical utility as the reason for not approving this drug. Let me check 2/3 fewer hypos than existing therapies might satisfy the clinical utility requirement.

Clinical utility is used to keep me too drugs from seeking approval (that plus the $1,000,000 NDA fee). If Al is correct in his assessment of where Afrezza fits into the diabetes drug armamentarium as a first choice drug, we will all look back in hindsight as the first CRL being plain and simple favoritism to big pharma.

Swing